XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
License, Collaboration, and Funding Agreements - Additional Information (Detail)
 3 Months Ended
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Collaboration License And Funding Arrangements [Line Items]    
Other income, net $ 105,000 $ 123,000
Research and Development Incentive    
Collaboration License And Funding Arrangements [Line Items]    
Grant receivable 700,000  
Other income, net 200,000 $ 100,000
Genzyme Agreement    
Collaboration License And Funding Arrangements [Line Items]    
Milestone Payments 20,000,000  
Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product $ 7,000,000  
Genzyme Agreement | 6% Net Sales    
Collaboration License And Funding Arrangements [Line Items]    
Revenue, Performance Obligation, Percentage of Net Sale 0.06  
Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer $ 150,000,000  
Genzyme Agreement | 10% Net Sales    
Collaboration License And Funding Arrangements [Line Items]    
Revenue, Performance Obligation, Percentage of Net Sale 0.10  
Genzyme Agreement | 10% Net Sales | Minimum    
Collaboration License And Funding Arrangements [Line Items]    
Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer $ 150,000,000  
Genzyme Agreement | 10% Net Sales | Maximum    
Collaboration License And Funding Arrangements [Line Items]    
Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer $ 300,000,000  
Genzyme Agreement | 12% Net Sales    
Collaboration License And Funding Arrangements [Line Items]    
Revenue, Performance Obligation, Percentage of Net Sale 0.12  
Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer $ 300,000,000